Pathology: la/mBC - HER2 positive - 2nd Line (L2);
| la/mBC - HER2 positive - 2nd Line (L2) | |||||||||
| LUX-Breast 1, 2016 | WJOG6110B/ELTOP, 2018 | EGF104900, 2010 | ExteNET, 2016 | NALA (brain metastases), 2020 | NALA, 2020 | HER2CLIMB (patients with brain metastases), 2020 | HER2CLIMB, 2020 | ||
| neratinib plus capecitabine | 2 | T1 | T1 | ||||||
| tucatinib plus trastuzumab plus capecitabine | 2 | T1 | T1 | ||||||
| lapatinib plus capecitabine | 1 | T1 | T0 | T0 | |||||
| afatinib plus vinorelbine | 1 | T1 | |||||||
| neratinib | 1 | T1 | |||||||
| lapatinib plus trastuzumab | 1 | T1 | |||||||
| trastuzumab plus capecitabine | 0 | T0 | T0 | T0 | |||||
| trastuzumab plus vinorelbine | 0 | T0 | |||||||
| placebo | 0 | T0 | |||||||
| lapatinib | 0 | T0 | |||||||